A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 6 Analysts

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on 4D Molecular Therapeutics FDMT in the last three months.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.0, a high estimate of $46.00, and a low estimate of $8.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 26.09%.

Decoding Analyst Ratings: A Detailed Look

A comprehensive examination of how financial experts perceive 4D Molecular Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to 4D Molecular Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
• Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 4D Molecular Therapeutics compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for 4D Molecular Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of 4D Molecular Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on 4D Molecular Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Delving into 4D Molecular Therapeutics's Background

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Financial Insights: 4D Molecular Therapeutics

Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.

Revenue Growth: 4D Molecular Therapeutics's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2024, the company experienced a revenue decline of approximately -99.99%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: 4D Molecular Therapeutics's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -1461433.33%, the company may encounter challenges in effective cost control.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -7.68%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): 4D Molecular Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -7.16%, the company demonstrates effective utilization of assets and strong financial performance.

Debt Management: 4D Molecular Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

Understanding the Relevance of Analyst Ratings

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.